Profile for ArQule, Inc. (ARQL)
« Back to company indexARQL Chatter Timeline
Stock Ticker for ARQL
Most Active Tweeters for ARQL
| User | Tweets |
|---|---|
| @storminvestor | 2 |
| @SPNewsAnalysis | 2 |
| @ohmsonite | 1 |
| @NewsToDesk | 1 |
| @intercooleronli | 1 |
Recent Tweets for ARQL
 |
@storminvestor ArQule, Inc. $ARQL Expected to Announce Earnings of -$0.11 Per Share https://t.co/AgjZDk8X5l July 25th 2017, 3:07pm |
 |
@SPNewsAnalysis ArQule, Inc. $ARQL Expected to Announce Earnings of -$0.11 Per Share https://t.co/WdEZDkAsdx July 25th 2017, 3:07pm |
 |
@StockSpotter $ARQL up 1.6% to 1.25 bullish at a cycle bottom #stocks #markets #trading https://t.co/XODN2Bzt6G July 25th 2017, 11:07am |
 |
@dailymailtimes ArQule, Inc. $ARQL Set to Announce Earnings on Tuesday https://t.co/GQEAQoc3m4 July 25th 2017, 8:07am |
|
@SPNewsAnalysis ArQule, Inc. $ARQL Set to Announce Earnings on Tuesday https://t.co/rPpplDs3qd July 25th 2017, 7:07am |
|
@storminvestor ArQule, Inc. $ARQL Set to Announce Earnings on Tuesday https://t.co/BdGg3zLXIT July 25th 2017, 7:07am |
 |
@intercooleronli ArQule, Inc. $ARQL Set to Announce Earnings on Tuesday https://t.co/BmVxirckks July 25th 2017, 7:07am |
 |
@ohmsonite @clarklsn2001 I'm looking at $ARQL and $LPTX. Don't blame me if they tank since biotech is high risk high return ?. Good luck! July 22nd 2017, 8:07pm |
 |
@StockNewsNow $ARQL ArQule To Report Second Quarter 2017 Financial Results On August 4, 2017 https://t.co/f8OisIjzaN July 21st 2017, 8:07am |
 |
@efinancialpub RT @NewsToDesk: $ARQL: ArQule To Report Second Quarter 2017 Financial Results On …: https://t.co/KVoa5kN9Bi July 21st 2017, 7:07am |
 |
@stockboardinc $ARQL ArQule To Report Second Quarter 2017 Financial Results On August 4, 2017... - https://t.co/0iqMu4zL3s July 21st 2017, 7:07am |
 |
@NewsToDesk $ARQL: ArQule To Report Second Quarter 2017 Financial Results On …: https://t.co/KVoa5kN9Bi July 21st 2017, 7:07am |
 |
@Allstocknews $ARQL ArQule To Report Second Quarter 2017 Financial Results On August 4, 2017 From our Stock News Alerts App July 21st 2017, 7:07am |
 |
@TheMarketsDaily ArQule $ARQL Earning Positive News Coverage, Report Shows https://t.co/mci5hdi8Ur July 13th 2017, 11:07am |
 |
@ZolmaxNews ArQule $ARQL Earning Positive News Coverage, Report Shows https://t.co/w9gZP4gwqi July 13th 2017, 8:07am |
 |
@1stOncology #ArQule Reports First Patient Dosed in Phase 1 Trial of BTK Inhibitor, #ARQ531, for B-cell Malignancies $ARQL https://t.co/YwT9KsHVJi July 12th 2017, 10:07am |
 |
@MaisaCorp $ARQL Begins Dosing Patients in Phase 1 Trial of BTK Inhibitor, ARQ 531, for B-cell Malignancies July 11th 2017, 4:07pm |
 |
@JNapodano $ARQL - Started P1 with BTK ARQ531 for B-cell malignancies. Initiation is on-time with previous guidance. Helps “Credibility” score. July 11th 2017, 2:07pm |
 |
@kuritzmike RT @odibro: $ARQL Announces First Patient Dosed in Phase 1 Trial of BTK Inhibitor, ARQ 531, for B-cell Malignancies https://t.co/7JPq94YdAM July 11th 2017, 2:07pm |
 |
@pharma_sector #ArQule Announces First Patient Dosed In Phase I Trial Of BTK Inhibitor, ARQ 531, For B-Cel... Read more: https://t.co/bpauzYSVzA $ARQL July 11th 2017, 12:07pm |
 |
@fortint RT @iciresearch: ArQule Announces First Patient Dosed in Ph 1 Trial of BTK Inhibitor, ARQ 531, for B-cell Malignancies $ARQL https://t.co/9… July 11th 2017, 12:07pm |
 |
@Jake132013 $ARQL Arqule Inc 1.33 Had 127,376 1 Month Highs. ARQL Last price 1.33 Last change +0.04 +3.10%. https://t.co/IWTwJshFms July 11th 2017, 11:07am |
 |
@FinSentS_NASDAQ $ARQL:US ArQule: First Patient Dosed In ARQ 531 Phase 1 Trial For B-cell Malignancies #ARQULE INC https://t.co/agO9V1HmAV #NASDAQ July 11th 2017, 10:07am |
|
@StockNewsNow $ARQL ArQule Announces First Patient Dosed in Phase 1 Trial of BTK Inhibitor, ARQ 531, for B-cell Malignancies https://t.co/Ioxs8suVQy July 11th 2017, 9:07am |
|
@pharma_sector #ArQule: First Patient Dosed In ARQ 531 Phase 1 Trial For B-cell Malignancies. Read more: https://t.co/fb3SRpkAIN $ARQL July 11th 2017, 9:07am |
 |
@focusblood #lymsm Dosed in Phase 1 Trial of BTK Inhibitor, ARQ 531, for B-cell Malignancies $arql July 11th 2017, 9:07am |
 |
@iciresearch ArQule Announces First Patient Dosed in Ph 1 Trial of BTK Inhibitor, ARQ 531, for B-cell Malignancies $ARQL https://t.co/9C9sNsrTtX July 11th 2017, 8:07am |
|
@stockboardinc $ARQL ArQule Announces First Patient Dosed in Phase 1 Trial of BTK Inhibitor, ARQ 531, for B-cell Malignan... - https://t.co/0hqra74Gbv July 11th 2017, 7:07am |
 |
@odibro $ARQL Announces First Patient Dosed in Phase 1 Trial of BTK Inhibitor, ARQ 531, for B-cell Malignancies https://t.co/7JPq94YdAM July 11th 2017, 7:07am |
|
@Allstocknews $ARQL ArQule Announces First Patient Dosed in Phase 1 Trial of BTK Inhibitor, ARQ 531, for B-cell Malignancie From our Stock News Alerts App July 11th 2017, 7:07am |
 |
@newswithvalue $ARQL: ArQule Announces First Patient Dosed in Phase 1 Trial of BTK …: https://t.co/d4BK6uABnw July 11th 2017, 7:07am |
 |
@IcemanTrading $ARQL Testing a big trend breakout. Closed over the 200SMA today with increased volume. #ICEMAN https://t.co/1LSAH6TQJf July 6th 2017, 8:07pm |
|
@pharma_sector #ArQule : Presents Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress... Read more: https://t.co/CdwNEDa2Mh $ARQL July 6th 2017, 8:07pm |
 |
@Greatstockpix $ARQL daily chart looks pretty good if today's move holds. July 5th 2017, 2:07pm |
|
@pharma_sector #ArQule Presents Preclinical Data for BTK Inhibitor, ARQ 531, at EHA. Read more: https://t.co/Wg3M6kxaLG $ARQL July 2nd 2017, 1:07am |
 |
@MyAlliesTrading $ARQL ArQule Presents Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European... https://t.co/0aqG7ulK2m July 1st 2017, 6:07am |
 |
@sarwood $ARQL really good looking chart. D Cup and handle with the handle turning into its on C&H lol, first pt is 2.00 June 30th 2017, 11:06am |
 |
@dailypoliticaln ArQule $ARQL Getting Favorable Media Coverage, Study Shows https://t.co/jnudCrN3X0 June 29th 2017, 12:06pm |
 |
@InsiderAlertsIA $ARQL: New Insider Filing on Director MICHAEL D LOBERG: https://t.co/DGsj4dKLft June 27th 2017, 12:06pm |
 |
@confcalltran ArQule director just picked up 1,000 shares https://t.co/qu0fZ7SRhq $ARQL June 27th 2017, 10:06am |
 |
@pennyomegaCRWE Law Firm Investigating $ARQL https://t.co/t0HQ4FZsG7 June 26th 2017, 5:06pm |
 |
@biopadawan RT @mngerfreedm: $ARQL Strategy and catalysts https://t.co/IrhnQJXpgn June 26th 2017, 4:06pm |
|
@pharma_sector #ArQule Presents Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress o... Read more: https://t.co/4FNJeAHxp0 $ARQL June 26th 2017, 4:06pm |
|
@dailypoliticaln ArQule $ARQL Getting Somewhat Positive Press Coverage, Study Finds https://t.co/wOWF4h4xKT June 26th 2017, 8:06am |
 |
@biostockinfo RT @TomSilver39: $ARQL #EHA17 ARQ 531, A Reversible BTK Inhibitor, Demonstrates Potent Anti-Tumor Activity In ABC-DLBCL And GCB-DLBCL https… June 26th 2017, 12:06am |
 |
@TomSilver39 $ARQL #EHA17 ARQ 531, A Reversible BTK Inhibitor, Demonstrates Potent Anti-Tumor Activity In ABC-DLBCL And GCB-DLBCL https://t.co/9Tv0tzOqp4 June 25th 2017, 5:06pm |
 |
@mngerfreedm $ARQL Strategy and catalysts https://t.co/IrhnQJXpgn June 25th 2017, 8:06am |
 |
@StockTipRobot A Whitehouse intern overheard that this stock is gonna be uuuge! So consider selling ArQule $ARQL #ProTip June 24th 2017, 8:06am |
|
@StockNewsNow $ARQL ArQule Presents Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European... https://t.co/O2rni9z5OQ June 23rd 2017, 2:06pm |
|
@kuritzmike RT @odibro: $ARQL Presents Preclinical Data for BTK Inhibitor, ARQ 531, at #EHA17 https://t.co/iP0apINKDS June 23rd 2017, 7:06am |
Contact © thinkBiotech LLC 2004 - 2017. All rights reserved.